RNA interference-based nanosystems for inflammatory bowel disease therapy

Jian Guo,1 Xiaojing Jiang,1 Shuangying Gui1,2 1Department of Pharmaceutics, College of Pharmacy, Anhui University of Chinese Medicine, 2Institute of Pharmaceutics, Anhui Academy of Chinese Medicine, Hefei, Anhui, People’s Republic of China Abstract: Inflammatory bowel disease (IBD), whic...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Guo J, Jiang XJ, Gui SY
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	RNA interference siRNA miRNA nanoparticles inflammatory bowel disease target therapy Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/fc13ba1e5e4b481b9ff97e6679173ec8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fc13ba1e5e4b481b9ff97e6679173ec8
record_format	dspace
spelling	oai:doaj.org-article:fc13ba1e5e4b481b9ff97e6679173ec82021-12-02T07:22:53ZRNA interference-based nanosystems for inflammatory bowel disease therapy1178-2013https://doaj.org/article/fc13ba1e5e4b481b9ff97e6679173ec82016-10-01T00:00:00Zhttps://www.dovepress.com/rna-interference-based-nanosystems-for-inflammatory-bowel-disease-ther-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Jian Guo,1 Xiaojing Jiang,1 Shuangying Gui1,2 1Department of Pharmaceutics, College of Pharmacy, Anhui University of Chinese Medicine, 2Institute of Pharmaceutics, Anhui Academy of Chinese Medicine, Hefei, Anhui, People’s Republic of China Abstract: Inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn’s disease, is a chronic, recrudescent disease that invades the gastrointestinal tract, and it requires surgery or lifelong medicinal therapy. The conventional medicinal therapies for IBD, such as anti-inflammatories, glucocorticoids, and immunosuppressants, are limited because of their systemic adverse effects and toxicity during long-term treatment. RNA interference (RNAi) precisely regulates susceptibility genes to decrease the expression of proinflammatory cytokines related to IBD, which effectively alleviates IBD progression and promotes intestinal mucosa recovery. RNAi molecules generally include short interfering RNA (siRNA) and microRNA (miRNA). However, naked RNA tends to degrade in vivo as a consequence of endogenous ribonucleases and pH variations. Furthermore, RNAi treatment may cause unintended off-target effects and immunostimulation. Therefore, nanovectors of siRNA and miRNA were introduced to circumvent these obstacles. Herein, we introduce non-viral nanosystems of RNAi molecules and discuss these systems in detail. Additionally, the delivery barriers and challenges associated with RNAi molecules will be discussed from the perspectives of developing efficient delivery systems and potential clinical use. Keywords: RNA interference, siRNA, miRNA, nanoparticles, inflammatory bowel disease, target therapyGuo JJiang XJGui SYDove Medical PressarticleRNA interferencesiRNAmiRNAnanoparticlesinflammatory bowel diseasetarget therapyMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 11, Pp 5287-5310 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	RNA interference siRNA miRNA nanoparticles inflammatory bowel disease target therapy Medicine (General) R5-920
spellingShingle	RNA interference siRNA miRNA nanoparticles inflammatory bowel disease target therapy Medicine (General) R5-920 Guo J Jiang XJ Gui SY RNA interference-based nanosystems for inflammatory bowel disease therapy
description	Jian Guo,1 Xiaojing Jiang,1 Shuangying Gui1,2 1Department of Pharmaceutics, College of Pharmacy, Anhui University of Chinese Medicine, 2Institute of Pharmaceutics, Anhui Academy of Chinese Medicine, Hefei, Anhui, People’s Republic of China Abstract: Inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn’s disease, is a chronic, recrudescent disease that invades the gastrointestinal tract, and it requires surgery or lifelong medicinal therapy. The conventional medicinal therapies for IBD, such as anti-inflammatories, glucocorticoids, and immunosuppressants, are limited because of their systemic adverse effects and toxicity during long-term treatment. RNA interference (RNAi) precisely regulates susceptibility genes to decrease the expression of proinflammatory cytokines related to IBD, which effectively alleviates IBD progression and promotes intestinal mucosa recovery. RNAi molecules generally include short interfering RNA (siRNA) and microRNA (miRNA). However, naked RNA tends to degrade in vivo as a consequence of endogenous ribonucleases and pH variations. Furthermore, RNAi treatment may cause unintended off-target effects and immunostimulation. Therefore, nanovectors of siRNA and miRNA were introduced to circumvent these obstacles. Herein, we introduce non-viral nanosystems of RNAi molecules and discuss these systems in detail. Additionally, the delivery barriers and challenges associated with RNAi molecules will be discussed from the perspectives of developing efficient delivery systems and potential clinical use. Keywords: RNA interference, siRNA, miRNA, nanoparticles, inflammatory bowel disease, target therapy
format	article
author	Guo J Jiang XJ Gui SY
author_facet	Guo J Jiang XJ Gui SY
author_sort	Guo J
title	RNA interference-based nanosystems for inflammatory bowel disease therapy
title_short	RNA interference-based nanosystems for inflammatory bowel disease therapy
title_full	RNA interference-based nanosystems for inflammatory bowel disease therapy
title_fullStr	RNA interference-based nanosystems for inflammatory bowel disease therapy
title_full_unstemmed	RNA interference-based nanosystems for inflammatory bowel disease therapy
title_sort	rna interference-based nanosystems for inflammatory bowel disease therapy
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/fc13ba1e5e4b481b9ff97e6679173ec8
work_keys_str_mv	AT guoj rnainterferencebasednanosystemsforinflammatoryboweldiseasetherapy AT jiangxj rnainterferencebasednanosystemsforinflammatoryboweldiseasetherapy AT guisy rnainterferencebasednanosystemsforinflammatoryboweldiseasetherapy
_version_	1718399495706771456

RNA interference-based nanosystems for inflammatory bowel disease therapy

Ejemplares similares